10-Q: CapsoVision Reports Q3 2026 Results Amidst Financial Concerns

CapsoVision, Inc. filed its Q3 2026 Form 10-Q, detailing a slight revenue increase but persistent operating losses and significant going concern doubts, while also announcing FDA clearance for its AI Highlights feature.

Summary

• CapsoVision, Inc. reported its quarterly results for the period ending September 30, 2026.
• Revenue for the three months ended September 30, 2026, was $3.6 million, a 1% increase from $3.5 million in the same period of 2025.
• Net loss for the three months ended September 30, 2026, was $7.3 million, an improvement from $7.9 million in the prior year's period.
• For the nine months ended September 30, 2026, revenue was $10.0 million, a 4% increase from $9.6 million in the prior year's period.
• Net loss for the nine months ended September 30, 2026, was $21.9 million, an increase from $17.9 million in the prior year's period.
• The company has substantial doubt about its ability to continue as a going concern.
• The company received FDA clearance for its AI Highlights feature on September 25, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to the company's continued net losses, substantial doubt about its going concern status, and increasing operating expenses, despite modest revenue growth.

Positives

• Revenue increased by 1% to $3.6 million for the three months ended September 30, 2026, compared to the same period in 2025.
• Revenue increased by 4% to $10.0 million for the nine months ended September 30, 2026, compared to the same period in 2025.
• Net loss for the three months ended September 30, 2026, decreased by 7% to $7.3 million compared to $7.9 million in the prior year's period.
• International sales showed growth, accounting for 24% of total revenue in Q3 2026 and 25% for the nine months ended September 30, 2026.
• FDA clearance for the AI Highlights feature was obtained on September 25, 2026, with commercialization beginning November 2, 2026.
• The company raised significant capital through a Private Placement ($14 million gross) in March 2026, a Registered Direct Offering ($18 million gross) in September 2026, and an ATM program ($1.7 million net) in Q3 2026.

Negatives

• The company has incurred net losses since inception and expects to continue incurring losses, with an accumulated deficit of $177.5 million as of September 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within one year after the issuance date of the financial statements.
• Costs of revenue increased by 11% for the three months and 14% for the nine months ended September 30, 2026, outpacing revenue growth.
• Gross profit decreased by 8% for the three months and 5% for the nine months ended September 30, 2026.
• Gross margin declined to 49% for the three months and 50% for the nine months ended September 30, 2026, from 54% in the prior year periods.
• Total operating expenses increased by 16% for the nine months ended September 30, 2026, driven by increases in R&D and G&A expenses.
• Net loss for the nine months ended September 30, 2026, increased by 22% to $21.9 million compared to $17.9 million in the prior year's period.
• The company has identified two material weaknesses in its internal control over financial reporting.

Risks

• The company has a history of net losses and expects to incur additional losses, raising substantial doubt about its ability to continue as a going concern.
• The company's ability to grow revenue is dependent on the successful and timely execution of its revenue growth strategy for CapsoCam Plus and the eventual commercialization of CapsoCam Colon.
• The company faces substantial geopolitical and trade risks associated with its operations in Asia, including potential supply chain disruptions and tariffs.
• Failure to obtain or delays in obtaining FDA 510(k) clearance for the second-generation CapsoCam Colon solution could adversely impact commercialization and revenue generation.
• Reimbursement rates from third-party payers, including Medicare, may not be adequate, potentially hindering the commercial success of its products.
• Reliance on single-source suppliers in Asia for critical components poses a significant supply chain risk.
• The company may require additional capital to support business growth, and this capital might not be available on favorable terms or at all, potentially diluting existing stockholders.
• The company faces regulatory challenges and potential delays in obtaining 510(k) clearance for its AI technology, including for updates to previously cleared AI technology.

Future Outlook

The company expects to continue incurring losses and significant cash expenditures in the foreseeable future as it scales its business, invests in R&D, expands sales and marketing, and covers public company costs. The company anticipates that its existing cash balance may not be sufficient to fund operations for the next 12 months and plans to pursue additional capital raising activities. Commercial impact of AI Highlights is anticipated in 2027.

Management Comments

• The company's mission is to transform lives through innovative medical solutions that improve the health of patients around the world.
• Management expects the addition of AI Highlights to accelerate CapsoCam Plus sales growth, with commercial impact anticipated in 2027.
• The company believes its CapsoCam family of products can be adapted to address new GI medical indications.
• Management is evaluating different strategies to obtain required funding for future operations, which may include public and private placements of equity and/or debt securities.

Industry Context

StockSavvy.ai notes that CapsoVision operates in the competitive medical technology sector, specifically capsule endoscopy. The company's focus on AI integration and expansion into new indications like pancreatic cancer reflects broader industry trends towards advanced diagnostics and personalized medicine. However, the company faces significant competition from established players and emerging technologies, as well as regulatory hurdles and reimbursement challenges common in the medical device industry.

Comparison to Industry Standards

• The company's gross margin of 49-50% for the nine-month period is lower than the typical gross margins seen in established medical device companies, which often exceed 60-70%.
• The net loss per share of ($0.44) for the nine months ended September 30, 2026, indicates a significant burn rate, which is common for early-stage medical device companies but requires careful monitoring.
• The company's reliance on external financing, with substantial capital raises in 2026, is typical for companies in this sector that require significant R&D and regulatory approval investments before achieving profitability.
• The company's pursuit of FDA clearance for AI-driven features aligns with industry trends where AI is increasingly being integrated into diagnostic tools to improve accuracy and efficiency.

Legal Proceedings

• The company is not presently a party to any litigation that, if determined adversely, would materially and adversely affect its business, financial condition, or results of operations.

Related Party Transactions

• Consulting agreement with a former Board member, Wen-Hung Tsai, who received an option to purchase 250,000 shares of Common Stock.
• Three of four participating investors in the March 2026 Private Placement were existing shareholders, investing $13.5 million.
• Two purchasers in the September 2026 Registered Direct Offering are related parties (beneficial owners of >5% of common stock): Star One Global Capital Limited purchased 878,734 shares, and Eliyahou Harari purchased 1,757,469 shares.
• Other material transactions with related parties included R&D expenses with a vendor holding an insignificant percentage of capital stock.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing capital raises and potential future equity issuances.
• The company's going concern status raises concerns for investors regarding the long-term viability of their investment.
• Employees may face uncertainty due to the company's financial situation and the need for potential future restructuring or cost-saving measures.
• Suppliers and manufacturers may face risks related to the company's ability to meet payment obligations if financing is not secured.
• Customers (medical practices, clinics, hospitals) may be impacted by potential product availability issues or delays in new product introductions.

Next Steps

• Submit 510(k) application for the second-generation CapsoCam Colon capsule in the fourth quarter of 2026.
• Commercialize AI Highlights in the US starting November 2, 2026, and in the EU in August 2026.
• Continue development and studies for the CapsoCam UGI system for early pancreatic cancer detection.
• Pursue additional capital raising activities to fund operations and growth plans.
• Commercialize the capsule delivery device in the first quarter of 2027.
• Obtain FDA clearance for the patency capsule, expected in the first quarter of 2027.

Key Dates

Recommendation

While the company has achieved FDA clearance for its AI Highlights feature and secured significant funding, the persistent net losses, substantial doubt about its going concern status, and increasing operating expenses present considerable risks. The modest revenue growth and delays in key product launches (CapsoCam Colon) warrant caution. A 'hold' recommendation reflects the potential for future growth driven by AI and new product introductions, balanced against the significant financial and operational challenges.

Keywords

Capsule Endoscopy, Medical Technology, Gastrointestinal Imaging, AI in Healthcare, FDA Clearance, CapsoCam Plus, CapsoCam Colon, Going Concern